Trial Profile
A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE DISKUS) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Acronyms FACTO
- Sponsors Chiesi Farmaceutici
- 20 Apr 2012 Additional locations (France, Netherlands, Spain) added as reported by ClinicalTrials.gov.
- 28 Sep 2011 Status changed from active, no longer recruiting to completed.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.